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ABSTRACT
Many economic analyses of immunization programmes focus on the benefits in terms of public-sector
cost savings, but do not incorporate estimates of the private cost savings that individuals receive from
vaccination. This paper considers the implications of Bahl et al.'s cost-of-illness estimates for typhoid
immunization policy by examining how community-level incidence estimates and information on dis-
tribution of costs of illness among patients and the public-health sector can be used in the economic
analysis of vaccination-programme options. The findings illustrate why typhoid vaccination pro-
grammes may often appear to be unattractive to public-health officials who adopt a public budgetary
perspective. Under many plausible sets of assumptions, public-sector expenditure on typhoid vaccina-
tion does not yield comparable public-sector cost savings. If public-health officials adopt a societal
perspective on the economic benefits of vaccination, there are many situations in which different vac-
cination programmes will make economic sense. The findings show that this is especially true when
public decision-makers recognize that (a) the incidence of typhoid fever is underestimated by blood
culture-positive cases and (b) avoided costs of illness represent a significant underestimate of the actu-
al economic benefits to individuals of vaccination.
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INTRODUCTION
Globally, there are an estimated 16 million cases of
typhoid fever annually, causing 600,000 deaths mainly
in developing countries (1). The World Health Orga-
nization recommends establishing typhoid fever
vaccination programmes in endemic areas, and the Vi
polysaccharide vaccine against typhoid fever has been
shown to be effective, inexpensive, and well-tolerated
(1). However, resources for implementing new and
existing immunization programmes in developing
countries are scarce, and the addition of new vaccines
to current immunization schedules has logistical and
financial difficulties (2).  Many countries have con-
cluded that they cannot afford to add new vaccines
(e.g. against hepatitis B) to their Expanded Programme
on Immunization (EPI), and public-health resources
are under constant pressure to be redirected to other
interventions.
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In their study of an urban slum (Govindpuri) in New
Delhi, India, Sinha et al. found that the incidence of
typhoid fever in children aged five years and below
was much higher than expected (3). Using household
survey data from the same population, Bahl et al. gene-
rated the first estimates of costs of illness associated
with typhoid fever at the community level in a deve-
loping country (4). Results of their study showed that
the costs of illness per episode of typhoid fever were
the highest in 2-5-year old children and that both hos-
pitalization and clinical resistance to ciprofloxacin dra-
matically increased the cost of illness. Finally, Bahl et al.
showed that the distribution of costs between private
individuals and the public sector varies by age group
(4). The public sector in India is estimated to bear 70%
of costs of illness in 2-5-year old children. In all other
age groups, the majority of costs of illness are borne by
private households. 
Many economic analyses of immunization pro-
grammes focus on the benefits in terms of public-sector
cost savings, but do not incorporate estimates of the
private cost savings that individuals receive from vac-
cination. This paper considers the implications of Bahl
et al.'s cost-of-illness estimates for typhoid immuniza-
tion policy by examining how community-level inci-
dence estimates and information on the distribution of
costs of illness among patients and the public-health
sector can be used in the economic analysis of vacci-
nation-programme options. 
Economic analysis of vaccination programmes 
Policy analyses of immunization programmes typically
seek to answer the question: which immunization pro-
gramme generates the best health outcomes per dollar
spent by the public-health system? Health outcomes
are commonly measured in terms of avoided cases,
avoided deaths, and/or avoided costs. These analyses
help decision-makers select programmes that maximize
health benefits with a given budget. Economic analyses
of immunization programmes typically measure the
benefits of those programmes using avoided costs of
illness (5-7)
Drummond et al. emphasize that the results of eco-
nomic analyses will vary depending on the perspective
assumed by the analyst (8). Most policy analyses of
vaccination programmes take a public-sector budgetary
perspective, i.e. they only look at avoided public-sector
budget costs, or costs borne by healthcare providers, to 
measure vaccination benefits (5-7). Only a few take a
societal perspective and measure the total costs of ill-
ness as the sum of avoided public and private costs (9).
To the best of our knowledge, none of the previous
economic analyses of vaccination programmes in the
literature has explicitly compared the public-sector
budget perspective with the societal perspective (pub-
lic plus private costs avoided) using actual field data
from a developing country.  
This study uses estimates of both public and private
costs of illness due to typhoid fever to analyze the eco-
nomic and public-health impacts of three kinds of pub-
licly-financed immunization programmes (school-
based vaccination, targeted vaccination of pre-school
children aged 2-5 years, and vaccination of the general
population). We illustrate the difference between look-
ing at the results of the economic analysis from a pub-
lic budgetary perspective only and a fuller accounting
of the economic benefits that includes cost savings to
private individuals. We report the sensitivity of cost-
benefit results to changes in three main sources of
uncertainty: (a) the incidence of typhoid fever in the
community, (b) the average cost of vaccination, and (c)
the proportion of the total economic benefits represented
by avoided costs of illness.
Background
Vi polysaccharide vaccine
The Vi polysaccharide vaccine is administered in one
dose, as an injection, with revaccination recommended
after three years (1). In most countries, it is indicated
for use in adults and children aged over 24 months,
while its efficacy in very young children needs to be
determined (1). Studies in endemic areas have found
that the efficacy of the Vi vaccine ranges from 55% to
75% (1,10). The Vi vaccine has a well-established safety
profile with low incidence of mild side-effects, whether
it is administered alone or with other vaccines (1).
Study population
The study area is a poor, densely-populated urban slum
located in Kalkaji, New Delhi, India. The socioeconomic
characteristics of the sample are described in the paper of
Bahl et al. (4). Sinha et al. reported that the annual inci-
dence of typhoid fever among all 0-40-year old residents
was 9.8 per 1,000 persons, and the annual incidence in
children aged less than five years was 27.3 cases per
1,000 persons (3). These are among the highest incidence
rates of typhoid fever reported anywhere in the world.
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Research design and fieldwork
The population of the study area was divided into clus-
ters with 70 households in each, and 26 such clusters
were randomly selected for active twice-weekly sur-
veillance for detection of cases with typhoid fever (3).
The residents in the remaining household clusters were
kept under only passive surveillance at health facilities
and neighbouring practitioners for detection of fever
cases. 
Blood specimens for culture were obtained from all
children, aged less than five years, who had fever (tem-
perature >38 °C), identified through active or passive
surveillance. Older children and adults had to have had
continuous fever for at least three days before a blood
specimen was obtained for culture. These methods
have been described in detail previously (3). 
In the study population, a total of 98 cases of cul-
ture-positive typhoid fever and 31 of culture-positive
paratyphoid were identified through both active and pas-
sive surveillance. Ninety-four culture-negative cases
exhibiting a characteristic clinical syndrome were also
treated as typhoid fever. This 'clinical' typhoid syn-
drome was defined as continuous high fever for seven
days or more with no other obvious causes and no
response to three days of anti-malarial therapy. A diag-
nosis of  'clinical' typhoid was made earlier, i.e. after
five days of fever, if the patient additionally had brady-
cardia or splenomegaly. Bahl et al. estimated the costs
of illness for  blood culture-positive Salmonella enter-
ica serotype Typhi, blood culture-positive S. enterica
serotype Paratyphi, and 'clinical typhoid' cases (4). 
Measurement and calculation of costs of illness
Data to calculate the private costs of illness were col-
lected through weekly in-person interviews conducted
in the patient's home (4). Private, or patient, costs of ill-
ness are the sum of direct medical, direct non-medical,
and indirect costs. Direct medical costs included out-
of-pocket expenditure on consultation fees, laboratory
tests, and medicines. Non-medical direct costs measu-
red out-of-pocket expenditure on transportation, spe-
cial foods and drinks, and other items. Indirect costs
were calculated as the product of days of work missed
by all household members and a monetary value of lost
productivity. [Over the course of the study period from
November 1995 to October 1996, the exchange rate
between the Indian rupee and the US dollar fluctuated
between INR 34.32 and 36.59 per US$. For the costs
of illness presented in this study, we have assumed an
average exchange rate over the period of US$ 1=INR
35.5. All costs are expressed in 1996 US$.] Public
costs of illness, or non-patient costs, were defined as
the costs borne by institutions or the public sector.
Public costs were the sum of costs of outpatient visits
or hospitalization in government hospitals, and labora-
tory tests and medicines provided free of charge to the
patient.  
Ex-ante costs of illness
The estimates of ex-ante costs-of-illness are the pro-
duct of the average cost of illness and the disease inci-
dence; they represent the per-capita expected annual
losses due to typhoid fever. Table 1 presents these esti-
mates for the entire study population and by age group.
These point estimates represent averages around which
the population's ex-ante costs of illness will be distri-
buted. The private ex-ante costs of illness are the costs
that households should expect to incur; the public ex-
ante costs of illness are the costs that the public health-
care system should expect to incur. 
The total private and public ex-ante costs were
higher for children aged 2-5 years (US$ 4.34) than
those for children aged 0-2 year(s) (US$ 0.70), indivi-
duals aged 5-19 years (US$ 0.90), and adult (US$ 0.06)
subjects. Given that the average daily wage rate for an
adult is US$ 1.97, these estimates imply that house-
holds could expect to lose two days' wages in the next
year because of typhoid fever in 2-5-year old children
and less than one-half day's wage due to typhoid fever
affecting household members in other age groups. 
The distribution of ex-ante costs between private
individuals and the public sector varies widely by age
group. The private costs are greater than public costs
for all age groups except 2-5-year old children. In the
2-5-year age group, however, public-sector costs (US$
3.32) are over three times greater than patient costs
(US$ 1.04). The ex-ante public costs of illness are so
high for 2-5-year old children because of the high inci-
dence of typhoid fever in this age group and the rela-
tively high rates of hospitalization. The private ex-ante
costs are also high for this age group because of lost
wages due to adult caretaking. The ex-ante public cost
for adults is zero, indicating that typhoid fever in
adults imposes little burden on the public sector.
Considering all age groups, however, expected public
costs (US$ 0.48) are roughly comparable to expected 
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patient costs (US$ 0.42). The ex-ante cost of illness
increases significantly for patients who exhibit antibio-
tic resistance and patients who were hospitalized (4).
These results underscore the benefits of typhoid pre-
vention in areas with antibiotic resistance and poor
case treatment [See the paper by Bahl et al. (4) for
more details, including sensitivity analyses conducted
by varying assumptions on daily wages, the non-
patient costs of outpatient visits, and the daily hospita-
lization costs].
vaccination campaign]. The third is a targeted vaccina-
tion campaign for pre-school children aged 2-5 years,
which is assumed to reach 80% of this age group. All
three programmes are assumed to be fully paid for by
government, i.e. no user-fees are charged.
Vaccine benefits
We measure the outcomes of each of the three publicly-
funded vaccination programmes in three different ways:
(a) The number of typhoid fever cases avoided, calcu-
Table 1. Incidence of typhoid fever, ex-ante costs of illness, and vaccine benefits, by age group (70% effectiveness)
Annual                                                                                         Expectedincidence (per                                       Per-capita vaccine benefits, number of1,000 person-    Annual ex-ante costs        discounted over 3-year cases of Age Population of years) of illness (US$) period (US$) typhoid fever(years) Govindpuri Blood +ve       prevented withgroup
typhoid from      Private    Public   Total      Private  Public   Total     100% vaccine   
active surveillance                                                                                    coverage
0-2 1,123 13.6 0.45 0.25 0.70 NA NA NA NA
2-5 2,011 34.9 1.04 3.32 4.34 1.81 5.79 7.55 147
5-19 8,370 11.7 0.59 0.31 0.90 1.03 0.54 1.57 206
>19 8,081 1.1 0.06 0.00 0.06 0.10 0.00 0.10 19
All ages 19,585 9.8 0.42 0.48 0.90 0.74 0.83 1.57 372
Blood +ve 
typhoid from 
active plus passive 
Age                                surveillance 
(years)                             and 'clinical' 
group                                diagnoses
0-2 1,123 24.5 0.79 0.45 1.24 NA NA NA NA
2-5 2,011 53.1 1.58 5.04 6.62 2.75 8.78 11.52 224
5-19 8,370 19.3 0.99 0.48 1.49 1.72 0.83 2.60 339
>19 8,081 6 0.31 0.03 0.34 0.54 0.05 0.59 102
All ages 19,585 17.5 0.79 0.45 1.24 1.27 1.52 2.80 665
NA=Indicates that there are no vaccine benefits in the 0-2-year age group because the Vi polysaccharide vaccine is
not indicated  for this age group
MATERIALS AND METHODS
Policy interventions 
We estimate the costs and benefits of three different
public-sector vaccination programmes in the study
area. The first is a mass vaccination campaign that is
assumed to reach 80% of the total population in the
study area. The second is a school vaccination cam-
paign that is assumed to reach 80% of the 6-19-year
old individuals [We do not have data on what percen-
tage of school-age children are enrolled in schools. We
assume that the vaccine would be made available to
any child in this target age group, whether they attend
school or not, via the health posts established for the
lated as the product of the incidence rate, cohort popu-
lation, vaccine effectiveness, and vaccine coverage, i.e.
the percentage of the population in an age cohort that
is vaccinated; (b) Public-sector cost savings, estimated
as the costs of illness avoided by public healthcare
providers; and (c) Total public and private costs of ill-
ness avoided. We assume that the Vi vaccine is  70%
effective for three years.
The first outcome measure is simply a non-moneta-
rized count of the number of typhoid fever cases avoided
by a vaccination programme. It is presumably of inte-
rest to both public-sector decision-makers and private
individuals. However, from an economic perspective 
the benefits must be compared with the costs, and it is
difficult to make such comparisons when the costs are
measured in monetary units and the benefits are not.
The second outcome measure is of particular interest to
public-sector decision-makers who focus on the finan-
cial cost savings to the public-health budget. The third
outcome measure reflects a broader societal perspec-
tive, combining both public and private-sector cost
savings. Increases in all three measures indicate better
programme performance. 
We measure the economic benefits of the Vi vaccine
by the avoided ex-ante cost of illness. If the vaccine
were 100% effective in preventing typhoid fever, the
expected benefits of the vaccine could be estimated by
the present value of the ex-ante cost of illness avoided
during the three years of protection. We calculate the
present value of total vaccine benefits over the assumed
three-year period of vaccine effectiveness by: 
Where, PVB=present value of the stream of vaccine
benefits to the vaccinated population; Public
COIj=annual ex-ante public-sector costs of illness
avoided by vaccinating an individual in age cohort j
(assuming that the vaccine is 70% effective); Private
COIj=annual ex-ante private costs of illness avoided by
vaccinating an individual in age cohort j (assuming
that the vaccine is 70% effective); nj=number of indi-
viduals vaccinated by the programme in age cohort j;
m=number of age cohorts; i=number of years the vac-
cine is effective; and r=real discount. The vaccine bene-
fits are reported in Table 1.
We assume the real (i.e. net of inflation) discount
rate to be 10%.
Vaccine costs
Field data on the costs of running the three different
kinds of Vi vaccination programmes in this study popu-
lation are not available. However, recent estimates of
the cost of typhoid vaccination in Viet Nam have been
prepared for the International Vaccine Institute based
on data from a vaccination trial conducted in Hue, Viet
Nam, in 2003. These cost estimates reflect the financial
recurrent cost of resources that would be required to
conduct a new Vi vaccination programme in Viet Nam.
The per-unit vaccination cost was calculated by dividing
the total reported expenditure on several cost items (e.g.
vaccine dose, syringe, safety box, labour) by the num-
ber of vaccinations given. The estimates represent the
'incremental' costs of providing the typhoid vaccine to
the target population in the sense that they assume that
the existing cold-chain and central administrative
structure have sufficient capacity to add the pro-
gramme without the requirement of investing in addi-
tional capacity. The direct recurrent costs are estimated
to range from US$ 0.79 to 1.58 per vaccine depending
upon the assumptions made about the amount and
value of the labour input needed for the vaccination
programme (Stewart J. Personal communication,
2004). These per-unit vaccine costs are assumed to
reflect the full costs of vaccine acquisition and delivery,
including the opportunity costs of resources used in vac-
cine provision. From a societal cost-benefit perspective,
one should add to these recurrent cost estimates the pri-
vate costs to an individual in terms of transportation and
time spent to obtain the vaccine.
Although there are numerous reasons why vaccina-
tion costs in India and Viet Nam may differ, we believe
that these cost estimates of vaccination for Viet Nam
are likely to be generally representative of costs that
one would expect in urban India. However, to address
the uncertainties in the cost estimates, we conduct our
cost-benefit analysis using five assumed values for the
per-capita cost of vaccination (Vc): US$ 0.75, US$
1.00, US$ 1.50, US$ 2.00, and US$ 3.00.  
Comparing costs and benefits
We compare the costs and benefits of the three vacci-
nation programmes using five different metrics. First,
we present a standard cost-effectiveness ratio: the dol-
lars spent by the public sector on vaccination per
typhoid fever case avoided:
Second, we present a ratio of the public-sector treat-
ment cost savings per dollar spent by the public sector
on vaccination:
Our third cost-effectiveness ratio combines the three
types of data in the first two cost-effectiveness ratios (i.e.
the number of typhoid cases avoided, the costs of the vac-
cination programme, and the public-sector cost savings). 
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(Public COIj + Private COIj)
(1+r)ij=1 i=1
m 3 (1)PVB = Σ nj Σ
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It is the public dollars spent on vaccination minus the pub-
lic-sector cost savings per typhoid fever case avoided: 
This cost-effectiveness ratio shows the net cost to
the public sector of avoiding a typhoid fever case, taking
into account the fact that the costs to the public sector of
vaccination are partially offset by reduced public-sector
treatment costs. The numerator is, thus, the net effect
on the public-health budget of avoiding a typhoid case.
If the public-sector cost savings are greater than the
vaccination programme costs, this numerator will be
negative, implying that vaccination both reduces the
public-health budget and saves typhoid cases, and is a
win-win policy intervention.
Fourth, we calculate the total net benefits in the
study area of each vaccination programme from the
public-sector budgetary perspective:
Fifth, we calculate the net benefits of each vaccina-
tion programme from the societal perspective:
Limitations of methods 
Several limitations of these benefit-cost calculations
need to be emphasized. First, it has been shown both
theoretically and empirically that the ex-ante cost of
illness underestimates the benefits of disease preven-
tion (11). The ex-ante private cost of illness does not
incorporate (a) the expected pain and suffering due to
typhoid fever, (b) the risks of mortality, or (c) the costs
individuals may incur for activities that prevent
typhoid fever. [Willingness-to-pay (WTP) for the Vi
vaccine is a more comprehensive measure of the bene-
fits of reducing the risk of typhoid fever. Individuals'
expressed WTP for the Vi vaccine would likely reflect
the reduction in ex-ante cost of illness, avoided pain
and suffering, avoided disability, and the avoided costs
of activities to prevent typhoid fever]. To explore the
sensitivity of our results to the magnitude of this under-
estimation of total economic benefits, we multiply ex-
ante cost-of-illness (public + private) estimates by a 'COI
correction factor'_α, that we vary from 1 (no correction)
to 4 (which implies that avoided costs of illness repre-
sent 25% of the total economic benefits).
Second, the actual incidence of typhoid fever in the
study area is difficult to estimate. To show the sensitivity
of these cost-benefit calculations to changes in the
incidence of typhoid fever in the study population, we
use two estimates of incidence. First, we use a conserva-
tive estimate based on blood culture-confirmed cases
detected by active surveillance (9.8 cases per 1,000).
Second, we use a higher estimate based on blood cul-
ture-confirmed cases detected by both active and pas-
sive surveillance, plus estimates of 'clinical typhoid'
(17.5 cases per 1,000).
Third, this analysis only considers the efficiency of
alternative Vi vaccine programmes, not the efficiency
of typhoid fever immunization programmes relative to
other public-health programmes, such as EPI, polio
eradication, or prevention of malaria or HIV/AIDS.
The magnitude of Vi vaccine benefits relative to other
health interventions will determine the priority placed
on typhoid fever immunization programmes relative to
other public-health programmes. This study also does
not compare the efficiency of Vi vaccine programmes
with other health interventions for typhoid fever,
including water and sanitation improvements, changes
in case treatment, or other vaccines for typhoid fever.
RESULTS
Panel A in Table 2 presents the results for the five dif-
ferent metrics for comparing costs and benefits of the
mass vaccination programme for different per-unit
vaccine costs, assuming an incidence rate in the study
area based on blood culture-positive cases detected from
active surveillance. Panels B and C show the same set
of results for a school-based immunization programme
and a pre-school vaccination programme respectively.
There are a number of interesting findings from these
calculations. 
If one looks only at the public cost of avoiding a
typhoid fever case (first cost-effectiveness ratio, metric 1),
mass vaccination (Panel A) and school-based vaccina-
tion (Panel B) look similar. However, pre-school vac-
cination (Panel C) looks much more attractive. At a
per-unit vaccine cost of US$ 1, the public vaccine cost
per typhoid case avoided is about US$ 50 for mass
vaccination and US$ 41 for school vaccination, but
only about US$ 14 for a targeted vaccination programme
for pre-school children. 
Total number of typhoid fever fever cases avoided
j=1
m




(Public COIj)/ _(1+r)ij=1 i=1
m 3
Σ nj Σ j=1
m
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An examination of the second metric (public treatment
cost savings per dollar spent on vaccination) shows that
from a public-sector budgetary perspective, the mass
vaccination and school vaccination programmes do not
look attractive at most per-unit vaccine costs, i.e. a dol-
lar spent on vaccination yields less than a dollar reduc-
tion in public-sector treatment cost savings.  However, a
dollar spent on vaccinating 2-5-year old children yields
more than a dollar reduction in public-sector treatment
cost savings at all vaccine costs shown.
From the perspective of the net public cost per
typhoid case avoided (metric 3), both mass vaccination
and school vaccination look attractive at low to moder-
ate vaccine costs.  For example, at a per-unit vaccine
cost of US$ 1, the net public cost of avoiding a case of
typhoid is US$ 6 for mass vaccination and US$ 19 for 
programmes is most stark. Mass vaccination and
school-based vaccination have negative net benefits at
almost all vaccine costs. The pre-school vaccination
programme has high net public benefits at all vaccine
costs shown in Table 2.
From an economic perspective, the net societal bene-
fits (metric 5) are the most important results. In terms of
net societal benefits, mass vaccination looks attractive at
low to moderate vaccine costs (net societal benefits are
positive for mass vaccination at a per-unit vaccine cost
of US$ 1.50, but become negative at higher per-unit
vaccine costs reported in Table 2). School-based vacci-
nation has slightly lower net societal benefits than mass
vaccination. On the other hand, the pre-school vaccina-
tion programme has positive net societal benefits at all
the per-unit vaccine costs shown in Table 2.
Table 2. Impacts and economic analyses of mass immunization programme, school-based immunization
programme, and pre-school immunization programme by vaccine cost (based on incidence of blood
culture-positive typhoid fever from active surveillance)
Programmes and programme metrics Vaccine cost (US$)
0.75 1 1.5 2 3
Panel A: Mass immunization programme
Number of cases avoided 297 297 297 297 297
Public cost/cases avoided (US$/case) 37.25 49.67 74.50 99.33 149.00
Public benefits (US$)/public cost (US$) 1.17 0.87 0.58 0.44 0.29
(Public cost public benefit)/cases avoided (US$/case) -6.20 6.22 31.05 55.88 105.55
Net public benefits (  public benefits public costs) (US$) 1,844 -1,849 -9,233 -16,618 -31,388
Net societal benefits (  total benefits public costs) (US$) 12,213 8,521 1,136 -6,249 -21,018
Panel B: School-based immunization programme
Number of cases avoided 165 165 165 165 165
Public cost/cases avoided (US$/case) 30.53 40.70 61.05 81.40 122.10
Public benefits (US$)/public cost (US$) 0.72 0.54 0.36 0.27 0.18
(Public cost public benefit)/cases avoided (US$/case) 8.57 18.75 39.10 59.45 100.15
Net public benefits (  public benefits public costs) (US$) -1,410 -3,084 -6,433 -9,781 -16,477
Net societal benefits (  total benefits public costs) (US$) 5,485 3,811 463 -2,885 -9,581
Panel C: Pre-school immunization programme
Number of cases avoided 118 118 118 118 118
Public cost/cases avoided (US$/case) 10.23 13.64 20.47 27.29 40.93
Public benefits (US$)/public cost (US$) 7.72 5.79 3.86 2.89 1.93
(Public cost public benefit)/cases avoided (US$/case) -68.72 -65.31 -58.48 -51.66 -38.02
Net public benefits (  public benefits public costs) (US$) 8,102 7,700 6,896 6,091 4,483
Net societal benefits (  total benefits public costs) (US$) 10,942 10,540 9,736 8,931 7,323
school-based vaccination. Pre-school vaccination is much
more attractive. At all per-unit vaccine costs shown,
this intervention saves money and typhoid fever cases;
in effect, the reduction in typhoid fever cases in this age
cohort can make money for the public sector. 
If one looks at the net benefits to the public sector
(metric 4), the distinction between the three vaccination
As shown in Table 3, the cost-benefit results for all of
these five metrics are sensitive to the assumptions one
makes about the incidence of typhoid fever in the study
population. Experienced epidemiologists are confident
that estimating the incidence using the number of
blood culture-positive cases detected even from active
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Table 3. Impacts and economic analysis of mass immunization programme, school-based immunization
programme, and pre-school immunization programme by vaccine cost (based on incidence of blood
culture-positive typhoid fever from active plus passive surveillance plus 'clinical' typhoid fever)
Programmes and programme benefits Vaccine cost (US$)
0.75 1 1.5 2 3
Panel A: Mass immunization programme
Number of cases avoided 532 532 532 532 532
Public cost/cases avoided (US$/case) 20.81 27.75 41.62 55.50 83.25
Public benefits (US$)/public cost (US$) 1.81 1.36 0.90 0.68 0.45
(Public cost  public benefit)/cases avoided (US$/case) -16.80 -9.87 4.01 17.88 45.63
Net public benefits (  public benefits  public costs) (US$) 8,943 5,251 -2,134 -9,519 -24,288
Net societal benefits (  total benefits  public costs) (US$) 28,669 24,977 17,592 10,207 -4,562
Panel B: School-based immunization programme
Number of cases avoided 271 271 271 271 271
Public cost/cases avoided (US$/case) 18.50 24.67 37.01 49.35 74.02
Public benefits (US$)/public cost (US$) 1.11 0.83 0.56 0.42 0.28
(Public cost  public benefit)/cases avoided (US$/case) -2.06 4.11 16.44 28.78 53.45
Net public benefits (  public benefits  public costs) (US$) 560 -1,114 -4,462 -7,811 -14,507
Net societal benefits (  total benefits  public costs) (US$) 12,381 10,707 7,359 4,011 -2,686
Panel C: Pre-school immunization programme
Number of cases avoided 179 179 179 179 179
Public cost/cases avoided (US$/case) 6.73 8.97 13.45 17.94 26.90
Public benefits (US$)/public cost (US$) 11.70 8.78 5.85 4.39 2.93
(Public cost  public benefit)/cases avoided (US$/case) -71.99 -69.75 -65.26 -60.78 -51.81
Net public benefits (  public benefits  public costs) (US$) 12,915 12,512 11,708 10,904 9,295
Net societal benefits (  total benefits  public costs) (US$) 17,332 16,930 16,126 15,321 13,713
of typhoid fever in the population. If one includes the
blood culture-positive cases from active plus passive
surveillance and the 'clinical' typhoid cases in the calcu-
lation of the incidence rate, the cost-benefit results for all
three vaccination programmes look much better. The net
societal benefits (metric 5) of all three vaccination pro-
grammes are positive even at a high per-unit vaccine cost
of US$ 2. Importantly, the net public benefits (metric 4)
are still negative for mass vaccination if the vaccine costs
are US$ 1.50 or higher and are negative for school-based
vaccination if vaccine costs are US$ 1 or higher. Pre-
school vaccination looks even more attractive from both
public and societal perspectives at all vaccine costs.
Just as epidemiologists are confident that the inci-
dence of typhoid fever is significantly higher than indi-
cated by blood culture-confirmed cases, economists
are confident that the avoided private costs of illness
are a significant underestimate of the actual economic
value of risk reduction that a typhoid vaccine provides
to individuals. Figure 1 shows how the net societal
benefits of the three vaccination  programmes change
for different 'correction factors' for the magnitude of this
underestimation of economic benefits, assuming an
incidence rate based on blood culture-positive cases
detected with active surveillance. Figure 2 shows the
same results for an incidence rate based on blood cul-
ture-confirmed and 'clinical' typhoid fever. Note that the
lines representing the mass immunization and school-
based programmes are so close that they cannot be dis-
tinguished from one another. 
In both the figures, the area lying above the lines
representing the mass immunization and school-based
programmes represents combinations of COI correc-
tion factors and vaccine prices for which programme
benefits are greater than programme costs. In this
region, all programmes make economic sense. The
area lying between the two lines shown on each graph
represents combinations of COI correction factors and
vaccine prices for which the pre-school programme
benefits are greater than the pre-school programme
costs__costs exceed benefits for the other two pro-
grammes. The area lying below the line representing
the pre-school programme represents combinations of
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programme benefits are less than programme costs for
all three vaccination programmes.
These sensitivity analyses show that, for moderate
values of this economic correction factor (1.5-2.0), all
three vaccination programmes easily pass a societal
cost-benefit test if incidence is based on active surveil-
lance of blood culture-positive and clinical typhoid fever,
and the per-unit vaccine cost is less than US$ 3. Even
if incidence is based only on blood culture-confirmed
cases detected with active surveillance (Fig. 1), all three
vaccination programmes still pass a societal cost-bene-
fit test at a per-unit vaccine cost of US$ 3 for a correc-
tion factor of 2. The pre-school vaccination programme
easily passes a societal cost-benefit test at all per-unit
vaccine costs shown even if the avoided public and
Fig. 1. Net societal benefits by COI correction factor and per-unit vaccine cost: sensitivity analysis  (Incidence




















































Per-unit vaccine cost (US$) Costs > benefits
(all programmes)
School-based Mass immunization Pre-school
Benefits > costs (all programmes)
COI=Costs of illness
Benefits > costs (pre-school programme only)
Costs > benefits (mass immunization and
school-based programmes)
Fig. 2. Net societal benefits by COI correction factor and per-unit vaccine cost: sensitivity analysis (Incidence
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(all programmes)
School-based Mass immunization Pre-school
Benefits > costs (all programmes)
COI=Costs of illness
Benefits > costs (pre-school programme only)
Costs > benefits (mass immunization and
school-based programmes)
Poulos C et al.J Health Popul Nutr Sep 2004320
private cost of illness overestimates the total economic
benefits  (implying ∝<1).
DISCUSSION
Immunizations not only prevent mortality and morbidity,
they also reduce the expenditure of public and private
resources, permitting increases in consumption or
investments that improve individuals' standards of liv-
ing. Despite these benefits, public immunization pro-
grammes must compete with other health interventions
and other sectors for resources. Economic studies of
immunization programmes often demonstrate the mag-
nitude of benefits of immunization programmes in
terms of public-sector budgetary cost savings, but only
a few include the private cost benefits to individuals as
well.  
When attempting to conduct cost-benefit analyses
of typhoid vaccination programmes, analysts confront
major uncertainties in a number of key input parame-
ters.  Three of the most important parameters are: (a)
the incidence of typhoid fever in the study population,
(b) the per-unit vaccine cost, and (c) the magnitude by
which avoided costs of illness underestimate the actu-
al economic benefits of risk reduction that vaccination
provides. The results presented in this paper illustrate
the sensitivity of cost-benefit calculations to changes
in these key assumptions.  
The findings illustrate why typhoid vaccination pro-
grammes may often appear to be unattractive to public-
health officials who adopt a public budgetary perspec-
tive. Under many plausible sets of assumptions, pub-
lic-sector expenditure on typhoid vaccination does not
yield comparable public-sector cost savings. Of
course, public-health officials need not adopt this deci-
sion criterion. If public-health officials have the finan-
cial resources to spend on typhoid vaccination and
adopt a societal perspective on the economic benefits
of vaccination, including not only public cost savings
but private cost savings as well, there are many situa-
tions in which different vaccination programmes will
make economic sense. Our findings show that this is
especially true when public decision-makers recognize
that (a) the incidence of typhoid fever is significantly
underestimated by blood culture-positive cases and (b)
avoided costs of illness represent a significant under-
estimate of actual economic benefits to individuals of
vaccination.  
On the other hand, the results presented in this paper
are illustrative for slum areas with very high incidence
of typhoid fever. Typhoid vaccination programmes
will look much less attractive from an economic point
of view in locations with lower incidence of typhoid
fever. For example, our results for a slum community
in New Delhi are different from those of Vollaard et al.,
who speculated that mass immunization against typhoid
fever would not be appropriate in Jakarta, Indonesia
(12).
Our cost-benefit calculations also illustrate the
important differences between a public budgetary and
a societal perspective on typhoid vaccination. From a
public-sector budgetary perspective, under a wide array
of conditions, mass vaccination and school-based vac-
cination programmes may appear to be unattractive
even in a slum with very high incidence rates. This is,
in large part, because standard policy interventions are
not well-targeted from a public budgetary perspective.
School vaccination misses the 2-5-year old children
who impose high costs on the public-sector budget.
Mass vaccinations would cover these 2-5-year old chil-
dren, but spend resources vaccinating adults, who impose
very low costs on the public-health budget.
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